Genmab A/S (WBO:GMAB)
€ 258.7 0.7 (0.27%) Market Cap: 16.74 Bil Enterprise Value: 12.91 Bil PE Ratio: 23.40 PB Ratio: 3.88 GF Score: 92/100

Genmab A/S at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 11:30PM GMT
James Patrick Quigley
JP Morgan Chase & Co, Research Division - Analyst

Good afternoon, everyone. I'm James Quigley, European pharma and biotech analyst at JPMorgan. It's my pleasure to welcome you all to the Genmab presentation.

With us today is Genmab's CEO, Jan van de Winkel. After Jan's presentation, there'll be a breakout session in the Yorkshire Room, which is out the door to the back and left.

So with that, over to you, Jan.

Jan G. J. van de Winkel;S;Co;Founder
Genmab A;President & CEO

/-- -

Thank you very much. So good afternoon, everybody. It's a real pleasure to join you once again at the Annual JPMorgan Healthcare Conference as we kick off 2020. So welcome to those of you who are participating via webcast as well. The slides from today's presentation will be made available for download in PDF format at the end of the presentation after the event.

So let's now get started. And this is what you're very familiar with. This presentation may contain forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot